Literature DB >> 8619991

Functional identification of the active-site nucleophile of the human 85-kDa cytosolic phospholipase A2.

Z Huang1, P Payette, K Abdullah, W A Cromlish, B P Kennedy.   

Abstract

Ser-228 has been shown to be essential for the catalytic activity of the human cytosolic phospholipase A2 (cPLA2). However, its involvement in catalysis has not yet been demonstrated. Using site-directed mutagenesis, active-site directed irreversible inhibitors, and the novel fluorogenic substrate 7-hydroxycoumarinyl gamma-linolenate, evidence is presented to show that the hydroxyl group of Ser-228 is the catalytic nucleophile of cPLA2. Replacement of Ser-228 by Ala, Cys, or Thr resulted in the inability of these mutants to mediate calcium ionophore induced PGE2 production in COS-7 cells cotransfected with the cPLA2 mutants and cyclooxygenase-1. Cell lysates from these transfected cells also had undetectable levels of cPLA2 phospholipid hydrolyase activity as did the affinity column purified S228A and S228C cPLA2 mutants overexpressed in insect cells. The loss in activity was not due to the inability of the mutant enzymes to translocate to the substrate lipid interface since the purified S228C cPLA2 mutant, like the wild type, translocated to the phospholipid membrane in the presence of calcium as judged by fluorescence energy transfer. However, when an activated substrate, 7-hydroxycoumarinyl gamma-linolenate (pKa approximately 7.8 for its leaving group) was used as substrate, there was a significant level of 7-hydroxycoumarin esterase (7-HCEase) activity (about 1% of wild type) associated with the purified S228CC cPLA2 mutant. The S228A cPLA2 mutant was catalytically inactive. Contrary to wild type cPLA2, the 7-HCEase activity of the thio-cPLA2 was not titrated by the irreversible active-site-directed inhibitor methyl arachidonyl fluorophosphonate, but rather titrated by one equivalent of arachidonyl bromomethyl ketone, an arachidonyl binding site directed sulfhydryl reagent. These results are compatible with the hydroxyl of Ser-228 being the catalytic nucleophile of cPLA2 and that cysteine can replace serine as the nucleophile, resulting ina thiol-cPLA2 with significantly reduced catalytic power.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8619991     DOI: 10.1021/bi952541k

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  15 in total

1.  Regulation of Wnt/beta-catenin pathway by cPLA2alpha and PPARdelta.

Authors:  Chang Han; Kyu Lim; Lihong Xu; Guiying Li; Tong Wu
Journal:  J Cell Biochem       Date:  2008-10-01       Impact factor: 4.429

2.  Differential inhibition of group IVA and group VIA phospholipases A2 by 2-oxoamides.

Authors:  Daren Stephens; Efrosini Barbayianni; Violetta Constantinou-Kokotou; Anna Peristeraki; David A Six; Jennifer Cooper; Richard Harkewicz; Raymond A Deems; Edward A Dennis; George Kokotos
Journal:  J Med Chem       Date:  2006-05-04       Impact factor: 7.446

3.  Diversity in secreted PLA2-IIA activity among inbred mouse strains that are resistant or susceptible to Apc Min/+ tumorigenesis.

Authors:  Marina Markova; Revati A Koratkar; Karen A Silverman; Vincent E Sollars; Melina MacPhee-Pellini; Rhonda Walters; Juan P Palazzo; Arthur M Buchberg; Linda D Siracusa; Steven A Farber
Journal:  Oncogene       Date:  2005-09-22       Impact factor: 9.867

4.  Induction of cyclo-oxygenase-2 expression by methyl arachidonyl fluorophosphonate in murine J774 macrophages: roles of protein kinase C, ERKs and p38 MAPK.

Authors:  W W Lin; B C Chen
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

5.  Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders.

Authors:  Kay Ahn; Douglas S Johnson; Benjamin F Cravatt
Journal:  Expert Opin Drug Discov       Date:  2009-07       Impact factor: 6.098

6.  Binding conformation of 2-oxoamide inhibitors to group IVA cytosolic phospholipase A2 determined by molecular docking combined with molecular dynamics.

Authors:  Varnavas D Mouchlis; Vasiliki Michopoulou; Violetta Constantinou-Kokotou; Thomas Mavromoustakos; Edward A Dennis; George Kokotos
Journal:  J Chem Inf Model       Date:  2012-01-10       Impact factor: 4.956

7.  Role of cytosolic phospholipase A2 in cytokine-stimulated prostaglandin release by human gallbladder cells.

Authors:  E M Grossmann; W E Longo; J E Mazuski; N Panesar; D L Kaminski
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

8.  Regulation of adhesion of AML14.3D10 cells by surface clustering of beta2-integrin caused by ERK-independent activation of cPLA2.

Authors:  Shigeharu Myou; Xiangdong Zhu; Evan Boetticher; Yimin Qin; Saori Myo; Angelo Meliton; Anissa Lambertino; Nilda M Munoz; Kimm J Hamann; Alan R Leff
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

9.  The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors.

Authors:  D da Fonseca Pacheco; A Klein; A de Castro Perez; C M da Fonseca Pacheco; J N de Francischi; I D G Duarte
Journal:  Br J Pharmacol       Date:  2008-05-12       Impact factor: 8.739

10.  Group IV phospholipase A(2)alpha controls the formation of inter-cisternal continuities involved in intra-Golgi transport.

Authors:  Enrica San Pietro; Mariagrazia Capestrano; Elena V Polishchuk; Alessio DiPentima; Alvar Trucco; Pasquale Zizza; Stefania Mariggiò; Teodoro Pulvirenti; Michele Sallese; Stefano Tete; Alexander A Mironov; Christina C Leslie; Daniela Corda; Alberto Luini; Roman S Polishchuk
Journal:  PLoS Biol       Date:  2009-09-15       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.